| (Values in U.S. Thousands) | Nov, 2025 | Aug, 2025 | May, 2025 | Feb, 2025 | Nov, 2024 |
| Sales | 0 | 170 | 170 | 170 | 180 |
| Sales Growth | -100.00% | unch | unch | -5.56% | +125.00% |
| Net Income | -1,600 | -2,700 | -3,790 | -2,710 | -2,700 |
| Net Income Growth | +40.74% | +28.76% | -39.85% | -0.37% | -23.85% |
Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada.
Fiscal Year End Date: 08/31